Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink

PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - Wedbush

Wedbush analyst, Liana Moussatos, reviewed the FDA's briefing documents for Intercept Pharmaceuticals (NASDAQ: ICPT) obeticholic acid (OCA) in primary biliary cholangitis (PBC) Advisory Committee meeting and does not see any major red flags for approval.

As the analyst anticipated, the FDA appears to be focused on the validity of the primary endpoints (ALP... More

Intercept Pharmaceuticals (ICPT) Briefing Docs 'Mostly In-Line' - FBR Capital

FBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the FDA released briefing documents ahead of the April 7 meeting of its Gastrointestinal Drugs Advisory Committee (GIDAC) to discuss ICPT's new New Drug Application (NDA) for approval to use obeticholic acid (OCA), which is the company's investigational treatment for primary... More

Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing Docs

Baird analyst Brian Skorney reiterated an Outperform rating and $332 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following positive FDA briefing documents.

Skorney commented, "Though we admit being scared by FDA's three-month delay, today's briefing docs are, what's the word?... More

Wells Fargo Upgrades Intercept Pharmaceuticals (ICPT) to Outperform

Wells Fargo upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $133.55 yesterday.

Intercept Pharma (ICPT) FDA Briefing Documents Posted

Intercept Pharma (NASDAQ: ICPT) FDA briefing documents posted. LINK

Biotech Seen Grinding Higher, Says RBC Capital (IBB)

RBC analyst Michael J. Yee doesn't thinks biotech will make a v-shaped rally, but he expects the sector to grind higher this year. In the note, Yee also touched on several individual stocks -- Celgene (NASDAQ: CELG), Biogen (NASDAQ: BIIB), Vertex Pharma (NASDAQ: VRTX), BioMarin Pharma (NASDAQ: BMRN), and Intercept Pharma (NASDAQ: ICPT).

"While we are not expecting an easy V-shaped rally, we do continue to... More